A quiet revolution in dementia care is slipping out of research labs and into Philadelphia exam rooms, and families are starting to feel it. On Wednesday, specialists from the Penn Memory Center joined WHYY’s Studio 2 to unpack what is changing: blood tests that can spot Alzheimer’s biology, new antibody drugs that slow decline for some patients, and prevention strategies that public health officials say could keep a chunk of future cases from ever developing. All of it lands in a city where older residents and their caregivers are already wrestling with rising costs and patchy support.
Blood tests bring Alzheimer’s biology to the doctor’s office
Researchers have zeroed in on blood biomarkers, especially phosphorylated tau species such as p‑tau217, that can identify Alzheimer’s biology with accuracy approaching cerebrospinal fluid testing and PET imaging. That opens the door to much wider screening than a spinal tap or brain scan can realistically offer.
A 2024 analysis in Nature Medicine found that p‑tau markers perform similarly to cerebrospinal fluid tests in many clinical settings, and research in JAMA Neurology has backed p‑tau217’s potential as a clinical screening tool.
Commercial labs are not waiting around. Quest Diagnostics began offering p‑tau217 testing in 2024, a move that could make confirmation testing more accessible for many patients.
Modest but meaningful drug options are already in clinics
Over the past three years, anti‑amyloid monoclonal antibodies have shifted from experimental infusions to real prescriptions for carefully selected patients with early disease.
Eisai and Biogen’s lecanemab (Leqembi) slowed clinical decline by roughly 27% in the Phase 3 Clarity AD program, while Eli Lilly’s donanemab (Kisunla) showed about a 35% slowing in the lower‑tau subgroup of the TRAILBLAZER‑ALZ 2 trial. Both companies and federal regulators have spotlighted those results in approval materials, as reflected in notices from Eisai/Biogen and Eli Lilly.
The benefits are modest and the logistics are intense, but for some families even a slower decline can feel like precious borrowed time.
What experts on the ground are telling families
Penn Memory Center clinicians told WHYY that earlier detection can give families more time to plan finances, legal documents and day‑to‑day care. It also creates fast‑growing demand for brain imaging, specialist appointments and social‑work support that many systems are not yet built to deliver.
On WHYY’s Studio 2, Jason Karlawish and Alison Lynn walked listeners through those trade‑offs, warning that testing without follow‑up services can leave relatives with more questions and tougher choices, not fewer. The Penn Memory Center continues to provide evaluation, opportunities to enroll in research and caregiver programs for Philadelphia patients and families, according to its staff page at Penn Memory Center.
Prevention: what policymakers and clinicians are emphasizing
Public health leaders are increasingly focused on what people and communities can change across a lifetime to lower dementia risk. The Lancet Commission’s 2024 update expanded its list to 14 modifiable risk factors and estimated that addressing them could delay or prevent roughly 45% of dementia cases globally, a case that planners are using to argue for prevention at the population level.
The World Health Organization’s risk‑reduction guidance echoes that theme, stressing control of vascular risk, treatment of hearing and vision loss, regular physical activity and careful management of diabetes and cholesterol as realistic steps to protect brain health.
What to watch next
In the near term, families and clinicians can expect broader use of plasma biomarker testing, more long‑term and real‑world data from antibody drug programs and a thicket of practical problems. Infusion capacity, MRI monitoring and registry reporting will play a big role in who actually receives treatment.
Coverage rules, safety monitoring requirements and the availability of specialists and infusion chairs will decide how much of the benefit seen in trials reaches patients in Philadelphia waiting rooms, even as the overall economic and caregiving burden remains very large for families and the health system.
For now, clinicians are urging families to connect with local memory‑care programs and social‑work teams to sort through testing options, treatment eligibility and available support before test results or new prescriptions arrive.
Sources: reporting and conversation on WHYY Studio 2; scientific analyses in Nature Medicine and JAMA Neurology; company and regulatory notices from Eisai/Biogen and Eli Lilly; commercial test rollout at Quest Diagnostics; prevalence and cost data from the Alzheimer's Association facts and figures; and prevention guidance from the Lancet Commission and the World Health Organization.
